PATENT CLAIM ANALYSIS

Application Number: 16181021
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-05
Patent Classification: ["548", "195000"]

Abstract:
Provided herein are novel compounds that inhibit ribonucleotide reductase (RR) by binding to RRM2 and interfering with the activity of the RRM1/RRM2 holoenzyme, as well as methods of synthesizing these novel compounds. The compounds may be used to inhibit RR activity and to treat various conditions associated with RRM2 expression, such as for example certain cancer types, mitochondrial diseases, or degenerative diseases.

Claim (Index 7):
The compound of  claim 3  having the formula:

Metadata:
- Claim Count in Document: 7.0
- Percentile: 98.0
- Lexical Diversity: 1.4
- Patent Class: 548.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14444172', '14754100', '15725181', '15418366', '13093389']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8767729858642843
- 35 USC 102 Novelty (BERT): 0.6311426659752462
- Combined Prediction Score: 0.8522099538753806
- Mean Citation Score: 676.5675299999998
- Max Citation Score: 721.0576
- Similarity Product: 528.245446450901

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test